Dahlia Biosciences is leading the development of cell-based RNA detection tools using CRISPR technology. The foundational RNA-targeting Cas9 technology was invented by Dr. Mitchell O’Connell and Dr. Sam Sternberg in the laboratory of Dr. Jennifer Doudna at UC Berkeley.

The company is dedicated to empower scientists to study and isolate cells at high resolution via sensitive, robust, and multiplexed RNA detection in both fixed and live cells. Their CRISPR based RNA detection reagents will plug seamlessly into existing flow cytometry workflows, reducing the time and cost-basis of research and development. Their kits and reagents can supercharge the many applicaitons based on fixed-cell analysis and live-cell sorting with wide-ranging implications for detection of disease to design of biomarkers and drugs.